Axogen Inc vs Marqeta Inc — how do they compare? Axogen Inc trades at $38.5 (market cap $2.06B), while Marqeta Inc trades at $16.21 (market cap $1.70B). The key difference: Axogen Inc is the larger of the two by market cap, and Axogen Inc is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| AXGN | MQ | |
|---|---|---|
Market Cap | $2.06B | $1.70B |
Sector | Technology | Technology |
52-Week High | $46.19 | $27.32 |
52-Week Low | $11.28 | $15.04 |
Enterprise Value | $1.98B | $999.94M |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $39.49, down 2.69% today, with a bearish technical signal despite recent earnings volatility. The company reported mixed quarterly results with Q3 2025 beating estimates but Q1 2026 missing expectations. Strong analyst sentiment persists with 84% buy ratings and a $47.60 consensus price target, though negative profit margins and recent technical weakness create uncertainty.
The outlook remains cautiously optimistic given strong institutional support and reimbursement progress, but investors face risks from persistent losses and competitive pressures. The stock's current position near support at $39 suggests potential for recovery if upcoming Q2 earnings meet or exceed the $0.09 EPS estimate.
Marqeta (MQ) trades at $16.43, up 3.53% with a bullish technical signal. The company reported mixed quarterly earnings, beating in Q1 2026 but missing in Q4 2025, with revenue growth from $507M in 2024 to $625M in 2025. A recent 1-for-4 reverse stock split took effect on July 1, 2026. Cash flow improved to a net positive $86M in 2025. Analyst consensus is a $19 price target with 32% buy ratings.
Outlook is cautiously optimistic given earnings volatility and high valuation multiples. Opportunities include European expansion and credit product growth, but risks involve thin net margins and potential fiduciary duty lawsuits. The stock's upside depends on sustained profitability and execution of strategic initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →